First Hawaiian Bank reduced its position in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,739 shares of the company’s stock after selling 854 shares during the period. First Hawaiian Bank’s holdings in AstraZeneca were worth $931,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. GAMMA Investing LLC lifted its position in shares of AstraZeneca by 21.1% in the first quarter. GAMMA Investing LLC now owns 3,559 shares of the company’s stock worth $241,000 after purchasing an additional 619 shares in the last quarter. Canandaigua National Bank & Trust Co. bought a new stake in AstraZeneca during the 1st quarter worth about $1,086,000. General Partner Inc. acquired a new position in shares of AstraZeneca during the 1st quarter worth about $52,000. HighPoint Advisor Group LLC bought a new position in shares of AstraZeneca in the 4th quarter valued at about $1,352,000. Finally, PNC Financial Services Group Inc. increased its position in shares of AstraZeneca by 1.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 234,341 shares of the company’s stock valued at $15,783,000 after acquiring an additional 3,225 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.
AstraZeneca Stock Up 0.2 %
AZN opened at $78.56 on Friday. The stock’s fifty day simple moving average is $76.10 and its 200 day simple moving average is $69.66. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $80.86. The stock has a market cap of $243.57 billion, a PE ratio of 38.51, a price-to-earnings-growth ratio of 1.41 and a beta of 0.48. The company has a current ratio of 0.89, a quick ratio of 0.70 and a debt-to-equity ratio of 0.73.
Analysts Set New Price Targets
Several research analysts recently commented on the company. The Goldman Sachs Group initiated coverage on AstraZeneca in a research report on Thursday, May 30th. They set a “buy” rating and a $97.00 price target for the company. BMO Capital Markets increased their price objective on AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Friday, April 26th. Argus boosted their target price on shares of AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, May 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, April 16th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.00.
View Our Latest Analysis on AstraZeneca
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Read More
- Five stocks we like better than AstraZeneca
- Following Congress Stock Trades
- Darden Stock Up After Q4 Earnings Beat, Cautious FY25 Outlook
- The Role Economic Reports Play in a Successful Investment Strategy
- Celsius Stock: Why Piper Sandler Forecasts a 50% Surge
- What Does Downgrade Mean in Investing?
- Accenture’s Stock Earnings Reveal an AI-Powered Growth Strategy
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.